Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 19/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.73 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.73 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.73 |
| ▸ | RICTOR | Q6R327 | 1/20 | 0.73 |
| ▸ | RPTOR | Q8N122 | 1/20 | 0.73 |
| ▸ | MAPKAP1 | Q9BPZ7 | 1/20 | 0.73 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24044692 | 1.00 | MTOR (1.00) | MTORKCNH2PIK3CDPIK3CARICTOR | |
| SCHEMBL17354044 | 1.00 | MTOR (1.00) | MTORKCNH2PIK3CDPIK3CARICTOR | |
| SCHEMBL16023975 | 0.94 | MTOR (1.00) | MTORKCNH2PIK3CDPIK3CARICTOR | |
| SCHEMBL16023988 | 0.92 | MTOR (1.00) | MTORKCNH2PIK3CDPIK3CARICTOR | |
| SCHEMBL17353998 | 0.90 | MTOR (1.00) | MTORKCNH2PIK3CARICTORRPTOR | |
| SCHEMBL24044688 | 0.89 | MTOR (0.80) | MTORKCNH2PIK3CDPIK3CARICTOR | |
| SCHEMBL17353992 | 0.89 | MTOR (1.00) | MTORKCNH2PIK3CDPIK3CARICTOR | |
| SCHEMBL16023976 | 0.89 | MTOR (1.00) | MTORKCNH2PIK3CDPIK3CARICTOR | |
| SCHEMBL17415488 | 0.89 | MTOR (0.79) | MTORKCNH2PIK3CDPIK3CARICTOR | |
| SCHEMBL19491822 | 0.87 | MTOR (0.82) | MTORKCNH2PIK3CDPIK3CARICTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2966079-B1 | PYRIDOPYRIMIDINE OR PYRIMIDOPYRIMIDINE COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | SHANGHAI INST MATERIA MEDICA CAS (CN) | 2021-11-24 | — | — | EP | disclosed |
| US-9796732-B2 | Pyridopyrimidine or pyrimidopyrimidine compound, prepration method, pharmaceutical composition, and use thereof | SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK CO., LTD. (CN) | 2017-10-24 | — | — | US | disclosed |
| US-9796732-B2 | Pyridopyrimidine or pyrimidopyrimidine compound, prepration method, pharmaceutical composition, and use thereof | SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK CO., LTD. (CN) | 2017-10-24 | — | — | US | disclosed |
| EP-2966079-A1 | PYRIDOPYRIMIDINE OR PYRIMIDOPYRIMIDINE COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2016-01-13 | — | — | EP | disclosed |
| US-20150368274-A1 | Pyridopyrimidine Or Pyrimidopyrimidine Compound, Prepration Method, Pharmaceutical Composition, And Use Thereof | FUDAN UNIVERSITY (CN) | 2015-12-24 | — | — | US | disclosed |
| US-20150368274-A1 | Pyridopyrimidine Or Pyrimidopyrimidine Compound, Prepration Method, Pharmaceutical Composition, And Use Thereof | FUDAN UNIVERSITY (CN) | 2015-12-24 | — | — | US | disclosed |
| WO-2014135028-A1 | PYRIDOPYRIMIDINE OR PYRIMIDOPYRIMIDINE COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | 中国科学院上海药物研究所 (CN) | 2014-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150368274-A1 | Pyridopyrimidine Or Pyrimidopyrimidine Compound, Prepration Method, Pharmaceutical Composition, And Use Thereof | MTOR, PIK3CA, RICTOR | MTOR 1/4885KCNH2 3914/4885PIK3CD 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.